Advertisement

American Journal of Cardiovascular Drugs

, Volume 4, Issue 1, pp 21–29 | Cite as

Calcineurin Inhibitor-Associated Early Renal Insufficiency in Cardiac Transplant Recipients

Risk Factors and Strategies for Prevention and Treatment
  • David A. BaranEmail author
  • Ira D. Galin
  • Alan L. Gass
Review Article

Abstract

Cardiac transplantation is the definitive treatment for eligible patients with end-stage cardiac failure. Techniques have evolved to reduce surgical mortality to under 5%. Immediate and subsequent long-term survival is more dependent on acute and chronic rejection and the complications of immunosuppressive therapy. Ten-year survival is greater than 50%.

The success of transplantation over the last 20 years has been largely due to the advances in immunosuppression. The most notable and dramatic milestone was the introduction of cyclosporine in the early 1980s, which resulted in a significant improvement in allograft and patient survival. Cyclosporine is a peptide that inhibits the immune system by suppressing T-helper cell activation via inhibition of calcineurin, a critical intracellular enzyme. Tacrolimus has a similar (but not identical) mechanism of action, and was introduced in the 1990s. Drugs such as cyclosporine and tacrolimus, generically referred to as calcineurin inhibitors, have become the cornerstones of immunosuppressive protocols.

As a group, calcineurin inhibitors have adverse effects, including neurotoxicity, hypertension, and nephrotoxicity, which complicate their use. Early renal insufficiency manifests as postoperative oliguria (<50 mL/h urine output) or rising serum creatinine levels. There are a variety of postulated causes for calcineurin inhibitor-associated early renal insufficiency including direct calcineurin inhibitor-mediated renal arteriolar vasoconstriction, increased levels of endothelin-1 (a potent vasoconstrictor), as well as decreased nitric oxide production and alterations in the kidney’s ability to adjust to changes in serum tonicity.

Once early renal insufficiency occurs, no single treatment has been shown to be effective. Approaches discussed in this paper include reduction in calcineurin inhibitor dosages, as well as various drugs to promote increased renal perfusion such as misoprostol and dopamine. In addition, the paper emphasizes the importance of ruling out other causes of renal insufficiency in the early postoperative period, including volume depletion, depressed cardiac output, and mechanical obstruction to urine flow.

Given that there is no highly efficacious treatment for this syndrome, ways to avoid its occurrence are desirable. One paper is referenced that suggests that avoidance of rapid changes in tacrolimus level during the first three days of therapy is associated with a low occurrence of early renal insufficiency.

Keywords

Tacrolimus Felodipine Misoprostol Calcineurin Inhibitor Nesiritide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors have provided no information on sources of funding. There are no conflicts of interest directly relevant to the content of this review.

References

  1. 1.
    Bennett LE, Keck BM, Hertz MI, 1, et al. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international registry for thoracic organ transplantation. Clin Transpl 2001, 25-40Google Scholar
  2. 2.
    Halloran PF, Lien J, Aprile M, et al. Preliminary results of a randomized comparison of cyclosporine and Minnesota Antilymphoblast Globulin. Transplant Proc 1982; 14: 627–30PubMedPubMedCentralGoogle Scholar
  3. 3.
    Dunn CJ, Wagstaff AJ, Perry CM, et al. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) in organ transplantation. Drugs 2001; 61: 1957–2016PubMedGoogle Scholar
  4. 4.
    Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323–89PubMedGoogle Scholar
  5. 5.
    Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63(12): 1247–97PubMedGoogle Scholar
  6. 6.
    Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc 2000; 32: 27S–44SPubMedGoogle Scholar
  7. 7.
    Kelly P, Kahan BD. Review: metabolism of immunosuppressant drugs. Curr Drug Metab 2002; 3: 275–87PubMedGoogle Scholar
  8. 8.
    Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: pathophysiology, incidence and management. Drug Saf 1999; 21: 471–88PubMedGoogle Scholar
  9. 9.
    Olyaei AJ, de Mattos AM, Bennett WM: Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384–9PubMedGoogle Scholar
  10. 10.
    Camara NO, Matos AC, Rodrigues DA, et al. Urinary retinol binding protein is a good marker of progressive cyclosporine nephrotoxicity after heart transplant. Transplant Proc 2001; 33: 2129–31PubMedGoogle Scholar
  11. 11.
    Sheikh-Hamad D, Nadkarni V, Choi YJ, et al. Cyclosporine A inhibits the adaptive responses to hypertonicity: a potential mechanism of nephrotoxicity. J Am Soc Nephrol 2001; 12: 2732–41PubMedGoogle Scholar
  12. 12.
    Halloran PF, Kung L, Noujaim J: Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc 1998; 30: 2167–70PubMedGoogle Scholar
  13. 13.
    Epstein A, Beall A, Wynn J, et al. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery 1998; 123: 456–60PubMedGoogle Scholar
  14. 14.
    Beall A, Epstein A, Woodrum D, et al. Cyclosporine-induced renal artery smooth muscle contraction is associated with increases in the phosphorylation of specific contractile regulatory proteins. Biochim Biophys Acta 1999; 1449: 41–9PubMedGoogle Scholar
  15. 15.
    Lacha J, Hubacek JA, Viklicky O, et al. TGF-betal gene polymorphism is a risk factor for renal dysfunction in heart transplant recipients. Transplant Proc 2001; 33: 1567–9PubMedGoogle Scholar
  16. 16.
    Aigner RM, O’Mara RE, Fueger GF, et al. Renography before heart transplantation in patients with cardiomyopathy. J Nucl Med 1998; 39: 2153–8PubMedGoogle Scholar
  17. 17.
    Camara NO, Matos AC, Rodrigues DA, et al. Early detection of heart transplant patients with increased risk of cyclosporinenephrotoxicity. Lancet 2001; 357: 856–7PubMedGoogle Scholar
  18. 18.
    Oppenheimer F, Hotter G, Bulbena O, et al. Urinary prostanoids excretion in kidney transplantation: its relationship to acute rejection and cyclosporineinduced nephrotoxicity. Transplant Proc 1994; 26: 2606–7PubMedGoogle Scholar
  19. 19.
    Baran DA, Galin I, Sandler D, et al. Tacrolimus in cardiac transplantation: efficacy and safety of a novel dosing protocol. Transplantation 2002; 74: 1136–41PubMedGoogle Scholar
  20. 20.
    Baran D, Galin I, Sandler D, et al. A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. Transplant Proc 2002; 34: 1834–5PubMedGoogle Scholar
  21. 21.
    Baran DA, Segura L, Kushwaha S, et al. Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant 2001; 20: 59–70PubMedGoogle Scholar
  22. 22.
    Kwok BW, Hunt SA. Neoplasia after heart transplantation. Cardiol Rev 2000; 8: 256–9PubMedGoogle Scholar
  23. 23.
    Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136–45PubMedPubMedCentralGoogle Scholar
  24. 24.
    Keay S, Oldach D, Wiland A, et al. Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients. Clin Infect Dis 1998; 26: 596–600PubMedGoogle Scholar
  25. 25.
    Lenner R, Padilla ML, Teirstein AS, et al. Pulmonary complications in cardiac transplant recipients. Chest 2001; 120: 508–13PubMedGoogle Scholar
  26. 26.
    Mihalov ML, Gattuso P, Abraham K, et al. Incidence of post-transplant malignancy among 674 solid-organ- transplant recipients at a single center. Clin Transplant 1996; 10: 248–55PubMedGoogle Scholar
  27. 27.
    Snell GI, Levvey BJ, Chin W, et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment. J Heart Lung Transplant 2002; 21: 540–6PubMedGoogle Scholar
  28. 28.
    Pescovitz MD, Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 2001; 38: S16–21PubMedGoogle Scholar
  29. 29.
    Pilmore HL, Dittmer ID. Caclineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal failure function in patients with coexisting chronic allograft nephropathy. Clin Transplant 2002 Jun; 16(3): 191–5PubMedGoogle Scholar
  30. 30.
    Pouteil-Noble C, Chapuis F, Berra N, et al. Misoprostol in renal transplant recipients: a prospective, randomized, controlled study on the prevention of acute rejection episodes and cyclosporin A nephrotoxicity. Nephrol Dial Transplant 1994; 9: 552–5PubMedGoogle Scholar
  31. 31.
    Darlametsos IE, Varonos DD. Role of prostanoids and endothelins in the prevention of cyclosporine- induced nephrotoxicity. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 231–9PubMedGoogle Scholar
  32. 32.
    Manasia AR, Leibowitz AB, Miller CM, et al. Postoperative intravenous infusion of alprostadil (PGE1) does not improve renal function in hepatic transplant recipients. J Am Coll Surg 1996; 182: 347–52PubMedPubMedCentralGoogle Scholar
  33. 33.
    Hansen JM, Christensen NJ, Fogh-Andersen N, et al. Effects of the prostacyclin analogue iloprost on cyclosporin-induced renal hypoperfusion in stable renal transplant recipients. Nephrol Dial Transplant 1996; 11: 340–6PubMedGoogle Scholar
  34. 34.
    Moran M, Mozes MF, Maddux MS, et al. Prevention of acute graft rejection by the prostaglandin El analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med 1990; 322: 1183–8PubMedGoogle Scholar
  35. 35.
    Ismail T, Ayres R, Kiff P, et al. Enisoprost in liver transplantation. Transplantation 1995; 59: 1298–301PubMedGoogle Scholar
  36. 36.
    Pollak R, Knight R, Mozes MF, et al. A trial of the prostaglandin El analogue, enisoprost, to reverse chronic cyclosporine-associated renal dysfunction. Am J Kidney Dis 1992; 20: 336–41PubMedGoogle Scholar
  37. 37.
    Uchino T, Belboul A, Olausson M, et al. Effect of FK 506 and lipo prostaglandin El on heart allograft survival in rats. Scand Cardiovasc J 1999; 33: 362–5PubMedGoogle Scholar
  38. 38.
    Baran D, Galin I, Sandler D, et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. Transplant Proc 2002; 34: 1872–3PubMedGoogle Scholar
  39. 39.
    Kim YJ, Park YH, Moon HK. Reduction of chronic cyclosporine nephrotoxicity by thromboxane synthase inhibition with OKY-046. Kidney Blood Press Res 1997; 20: 38–43PubMedGoogle Scholar
  40. 40.
    Perico N, Rossini M, Imberti O, et al. Thromboxane receptor blockade attenuates chronic cyclosporine nephrotoxicity and improves survival in rats with renal isograft. J Am Soc Nephrol 1992; 2: 1398–404PubMedGoogle Scholar
  41. 41.
    Mobb GE, Whiting PH, Feehally J, et al. The effect of the thromboxane receptor antagonist GR32191B on cyclosporine-induced nephrotoxicity. Transplant Proc 1991; 23: 1241–3PubMedPubMedCentralGoogle Scholar
  42. 42.
    Petric R, Freeman D, Wallace C, et al. Modulation of experimental cyclosporine nephrotoxicity by inhibition of thromboxane synthesis. Transplantation 1990; 50: 558–63PubMedGoogle Scholar
  43. 43.
    Torras J, Valles J, Sanchez J, et al. Prevention of experimental cyclosporine nephrotoxicity by dietary supplementation with LSL 90202, a lysine salt of eicosapentaenoic acid: role of thromboxane and prostacyclin in renal tissue. Nephron 1994; 67: 66–72PubMedGoogle Scholar
  44. 44.
    Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int Suppl 1992; 36: S87–93PubMedGoogle Scholar
  45. 45.
    Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of diltiazem and the prostacycline analogue iloprost in human renal transplantation. Ren Fail 1992; 14: 289–96PubMedGoogle Scholar
  46. 46.
    Madsen JK, Sorensen SS, Hansen HE, et al. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 1998; 13: 2327–34PubMedGoogle Scholar
  47. 47.
    Wagner K, Albrecht S, Neumayer HH. Prevention of post transplant acute tubular necrosis by the calcium antagonist diltiazem: a prospective randomized study. Am J Nephrol 1987; 7(4): 287–91PubMedGoogle Scholar
  48. 48.
    Lopau K, Kleinert D, Erler J, et al. Tacrolimus in acute renal failure: does Larginine-infusion prevent changes in renal hemodynamics? Transpl Int 2000; 13: 436–42PubMedGoogle Scholar
  49. 49.
    Koller-Strametz J, Wolzt M, Fuchs C, et al. Renal hemodynamic effects of Larginine and sodium nitroprusside in heart transplant recipients. Kidney Int 1999; 55: 1871–7PubMedGoogle Scholar
  50. 50.
    Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38: 923–31PubMedGoogle Scholar
  51. 51.
    Bennett WM, Burdmann EA, Andoh TF, et al. Nephrotoxicity of immunosuppressive drugs. Nephrol Dial Transplant 1994; 9 Suppl. 4: 141–5PubMedGoogle Scholar
  52. 52.
    Bennett WM, Lindsley J, Buss WC. The effects of age and dosage route on experimental cyclosporine nephrotoxicity. Transplantation 1991; 51: 730–1PubMedGoogle Scholar
  53. 53.
    Rinaldi M, Pellegrini C, D’Armini AM, et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001; 19: 696–701PubMedGoogle Scholar
  54. 54.
    Carrier M, White M, Perrault LP, et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999; 18: 1218–23PubMedGoogle Scholar
  55. 55.
    Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769–72PubMedGoogle Scholar
  56. 56.
    Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288: 2547–53PubMedGoogle Scholar
  57. 57.
    Varriale P. Role of dopamine in congestive heart failure: a contemporary appraisal. Congest Heart Fail 1999; 5: 120–4PubMedGoogle Scholar
  58. 58.
    Varriale P, Mossavi A. The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function? Clin Cardiol 1997; 20: 627–30PubMedGoogle Scholar
  59. 59.
    Maleck WH, Piper SN, Koetter KP. Use of dopamine in acute renal failure. Crit Care Med 2002; 30: 1934–6PubMedGoogle Scholar
  60. 60.
    Marik PE. Low-dose dopamine: a systematic review. Intensive Care Med 2002; 28: 877–83PubMedGoogle Scholar
  61. 61.
    Gambaro G, Bertaglia G, Puma G, et al. Diuretics and dopamine for the prevention and treatment of acute renal failure: a critical reappraisal. J Nephrol 2002; 15: 213–9PubMedPubMedCentralGoogle Scholar
  62. 62.
    Woo EB, Tang AT, el-Gamel A, et al. Dopamine therapy for patients at risk of renal dysfunction following cardiac surgery: science or fiction? Eur J Cardiothorac Surg 2002; 22: 106–11PubMedGoogle Scholar
  63. 63.
    Reddy VG. Prevention of postoperative acute renal failure. J Postgrad Med 2002; 48: 64–70PubMedGoogle Scholar
  64. 64.
    Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double- blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184–9PubMedGoogle Scholar
  65. 65.
    Cheng JW. Nesiritide: review of clinical pharmacology and role in heart failure management. Heart Dis 2002; 4: 199–203PubMedGoogle Scholar
  66. 66.
    Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002; 144: 1102–8PubMedGoogle Scholar
  67. 67.
    Anonymous. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-40Google Scholar
  68. 68.
    Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001; 88: 35–9PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Heart Failure and Transplant ResearchNewark Beth Israel Medical CenterNewarkUSA
  2. 2.Mt Sinai HospitalNew YorkUSA

Personalised recommendations